
Opinion|Videos|December 20, 2024
Dosing Frequency, and Adverse Event Management With Bispecific Therapy
Panelists discuss how an early adverse event for this drug class no matter what the mechanism or target is, is cytokine release syndrome (CRS), and it tends to occur on a timescale that is predictable. When treating patients in the outpatient setting, they receive dexamethasone, given at the first fever, which is the first sign of cytokine release syndrome (CRS) and helps mitigate it.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe the CRS and ICANS that we see with the bispecifics, both BCMA and GPRC5D, and how we are approaching treating these patients in the inpatient and outpatient setting?
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
3
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
4
PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data
5


